Business
Mymetics Reports Successful Preclinical Study Results with COP-Virosomes as Second-Generation Allergy Immunotherapy
Mymetics Reports Successful Preclinical Study Results with COP-Virosomes as Second-Generation Allergy Immunotherapy.
About this update from Mymetics Corp.
[{"type":"text","content":"Second-generation Allergen Immunotherapy with COP-virosomes, based on Anergis Contiguous Overlapping Peptides (COP) linked to Mymetics' virosomes were tested by Stallergenes Greer in a therapeutic model of birch pollen allergy.The results showed that a treatment with COP-virosomes was able to cure allergic asthma in birch pollen sensitized mice.The COP-virosomes were significantly superior to the COP or the virosome alone, confirming the synergy between COP and virosomes to foster an improved second generation AIT treatment.The results of the study will soon be published.EPALINGES, SWITZERLAND / ACCESSWIRE / May 28, 2020 / Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines and immunotherapies against life threatening and life disabling diseases, announced today that Stallergenes Greer, a worldwide leader in allergen immunotherapy (AIT) and Anergis, a leader in ultra-fast AIT research and development, reported the results of a joint research study evaluating the effects of the second generation Contiguous Overlapping Peptides (COP) allergen immunotherapy in a therapeutic model of birch allergy, with the aim of shortening the AIT administration schemes.In 2018, Anergis and Mymetics reported that the COP-Virosomes were able to elicit a strong boost in TH1 antibody response without any IgE response, unlike the first generation of Anergis' COPs associated with aluminum hydroxide.In this new study conducted by Stallergenes Greer, COP-Virosomes, and COP and virosomes alone were compared to a placebo group in an in-house therapeutic model of birch pollen allergy. Recombinant Bet v 1 alone (the major allergen of birch pollen) and birch extract were also used as controls in this setting.COP-virosomes were the only synthetic therapy able to fully reverse asthma symptoms as well as lung inflammation (i.e. significant reduction in eeosinophils in bronchial fluids). Pro-allergic immune responses also decreased with COP-virosome therapy with a significant decrease of the IL-4, a Th2 cytokine. The results of the study will soon be published."This new data confirms that COP-virosomes are likely to be more efficacious clinically than a recombinant allergen or than our first generation COP allergy vaccines which did not include the Mymetics' virosomes. COP-virosomes m...